LTP2 Results Analysis-Showe-Wistar-2024

Abbreviated Name
LTP2 Results Analysis-Showe-Wistar-2024
Lead Investigator
Showe, Louise C. — Wistar
Coordinating Investigator
Zheng, Yingye — Fred Hutchinson Cancer Center
Involved Investigators

Abstract

No abstract availalbe.

Aims

We propose to analyze LTP2 PAXgene samples on this platform. ese studies are proof of principle that it is possible to transition a signature developed on microarrays to the Nanostring platform with no loss of accuracy and with improved performance using a simplified assay that requires very little sample manipulation. Blood samples collected in PAXgene Blood RNA is to be purified with PAXgene Blood miRNA Kit, (PreAnalytiX) according to the manufacturer’s instruction. RNA samples were quantitated on the NanoDrop 1000 Spectrophotometer (Thermo Fisher Scientific; Waltham, MA) and measured for quality on the Agilent 2100 Bioanalyzer (Santa Clara, CA. 100 nanograms of total RNA are analyzed using the Nanostring nCounter Analysis System that utilizes a color-coded barcode technology for measuring gene expression with high sensitivity (< 1 copy per cell). The custom panel includes probes for 20 housekeeping genes for normalization and a control Universal Human RNA is run with every 24 samples. Biomarker analysuys and scoring will be carried out using SVM-RFE.

Analytic Method

No analytic method available.

Publications

  • No publications available at this time for this protocol.

Biomarkers

  • No biomarkers available at this time for this protocol.

Data Collections

  • No data collections available at this time for this protocol.
Protocol ID
556
Protocol Type
Reference Set
Fields of Research
  • Nanotechnology
Collaborative Group
Lung and Upper Aerodigestive Cancers Research Group
Cancer Types
  • Malignant neoplasm of bronchus and lung

Associated Forms